LENSAR, Inc. LNSR R2K
Healthcare · Medical Devices · United States
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
READ MORE ›$5.80
-57.13% 1Y
Market & Price
Market Cap
$70.21M
Current Price
$5.80
High / Low (52W)
$13.54 / $5.09
Beta
0.84
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.89
Price to Book
6.50
P/S
1.22
EV/EBITDA
-6.17
Dividend Yield
-
Profitability & Returns
ROCE
-79.65%
ROE
-
ROA
-14.73%
Profit Margin
50.94%
Op Margin
49.24%
EPS (Latest Qtr)
$0.00
EPS (TTM)
$-0.55
Balance Sheet & Liquidity
Debt/Equity
0.10
Quick Ratio
1.05
Current Ratio
2.38
Debt
$2.57M
Total Assets
$71.43M
Current Assets
$46.77M
Working Capital
$6.20M
Ownership
Promoter Holding
21.50%
Chg in Prom Hold
-
FII / Inst Holding
52.78%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$73.07M
Total Revenue (TTM)
$57.70M
EBITDA
$-11.84M
Free Cash Flow
$-17.20M
Operating Cash Flow
$-12.16M
Shares Outstanding
12.10M
Gross Margin
45.71%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
18.23%
Profit 5Y
-24.05%
Revenue (YoY)
-5.20%
Earnings (YoY)
-
PROS
- Excellent profit margin of 50.9%.
- Compounding revenue at 18.2% over 5 years.
CONS
- Earnings shrank at -24.0% CAGR over 5 years.
- Trading 57.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LNSR LENSAR, Inc. R2K | 5.80 | - | $70.21M | - | -79.65% | - | 18.23% | -24.05% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 6.96M | 4.93M | 4.58M | 6.07M | 5.93M | 6.78M | 6.99M | 7.94M | 6.62M | 6.28M | 6.62M | 10.32M | 8.27M | 8.64M | 10.68M | - | - | 14.16M | 13.94M | 14.32M | 16.02M | 13.43M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.03M | 6.91M | 8.28M | 9.09M | 7.05M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.12M | 7.02M | 6.04M | 6.94M | 6.38M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.91M | 13.31M | 13.62M | 11.86M | 4.14M |
| Operating Income | - | - | -5.34M | -3.10M | -3.84M | -4.71M | -5.20M | -4.38M | -6.17M | -6.68M | -6.80M | -4.08M | -4.36M | -2.87M | -2.04M | -2.85M | -5.28M | - | - | -5.79M | -6.29M | -7.58M | -4.92M | 2.24M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.71M | -5.19M | -6.42M | -3.75M | 3.37M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.34M | -1.76M | -3.71M | -1.46M | 36.33M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.58M | -3.79M | -5.82M | -3.69M | -4.50M | -4.76M | -5.18M | -4.36M | -6.16M | -6.67M | -6.76M | -3.99M | -4.27M | -8.75M | 2.57M | -2.16M | -9.04M | - | - | -27.34M | -1.76M | -3.71M | -1.46M | 36.33M |
| Diluted EPS | - | - | - | - | - | - | - | -0.47 | -0.65 | -0.67 | -0.67 | -0.39 | -0.40 | -0.81 | -0.23 | -0.19 | -0.79 | - | - | -2.32 | -0.15 | -0.31 | -0.12 | 0.00 |
| R&D Expense | - | - | 4.33M | 1.57M | 1.43M | 2.00M | 2.75M | 3.01M | 3.18M | 4.79M | 3.83M | 1.58M | 1.65M | 1.50M | 1.53M | 1.44M | 1.35M | 1.20M | - | 1.53M | 1.43M | 1.37M | - | 1.39M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 26.35M | 22.78M | - | 35.36M | 42.16M | 53.49M | 58.44M |
| Cost of Revenue | - | - | - | 15.40M | 21.06M | 27.64M | 31.31M |
| Gross Profit | - | - | - | 19.95M | 21.11M | 25.85M | 27.12M |
| Operating Expenses | - | - | - | 40.13M | 33.34M | 32.79M | 51.70M |
| Operating Income | -12.71M | -18.50M | - | -20.18M | -12.23M | -6.94M | -24.58M |
| EBITDA | - | - | - | -16.77M | -8.71M | -3.00M | -20.08M |
| Interest Expense | - | - | 0 | - | - | - | - |
| Pretax Income | - | - | - | -19.91M | -14.38M | -31.40M | -34.28M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -14.66M | -19.77M | - | -19.91M | -14.38M | -31.40M | -34.28M |
| Diluted EPS | - | - | - | -1.96 | -1.31 | -2.73 | -2.87 |
| R&D Expense | 7.57M | 7.55M | 12.36M | 11.81M | 6.14M | 5.33M | 5.62M |
Compounded Sales Growth
| 5 Years: | 18.23% |
| 1 Year: | -5.20% |
Compounded Profit Growth
| 5 Years: | -24.05% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -57.13% |
| 6 Months: | -42.12% |
| 3 Months: | -51.55% |
| 1 Month: | +7.61% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 34.54M | 79.12M | - | 55.84M | 69.58M | 66.30M | 71.43M |
| Current Assets | - | - | - | - | 33.72M | 46.44M | 41.98M | 46.77M |
| Cash & Equivalents | - | 4.62M | 40.60M | - | 14.67M | 20.62M | 16.26M | 12.97M |
| Inventory | - | - | - | - | 11.74M | 15.69M | 11.43M | 21.52M |
| Receivables | - | - | - | - | 6.04M | 4.00M | 6.08M | 6.38M |
| Total Liabilities | - | 65.09M | 11.91M | - | 13.86M | 36.16M | 61.44M | 97.45M |
| Current Liabilities | - | 7.83M | 8.47M | - | 11.42M | 11.63M | 15.00M | 40.57M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 2.80M | 2.31M | 2.61M | 2.73M |
| Total Equity | -20.46M | -30.55M | 67.21M | - | 41.98M | 33.43M | 4.86M | -26.02M |
| Shares Outstanding | - | - | - | - | 11.09M | 11.33M | 11.65M | 11.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.59M | -13.79M | - | -14.86M | -9.66M | -2.27M | -14.83M |
| Investing Cash Flow | -2.09M | -326.00K | - | -115.00K | -4.16M | -2.16M | 1.28M |
| Financing Cash Flow | 15.95M | 50.00M | - | -1.99M | 19.76M | 78.00K | 10.26M |
| Capital Expenditure | -389.00K | -366.00K | - | -115.00K | -236.00K | -156.00K | -83.00K |
| Free Cash Flow | -12.98M | -14.16M | - | -14.97M | -9.89M | -2.43M | -14.91M |
| Net Change in Cash | - | - | - | -16.96M | 5.95M | -4.36M | -3.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 56.4% | 50.1% | 48.3% | 46.4% |
| Operating Margin % | -48.3% | -81.2% | - | -57.1% | -29.0% | -13.0% | -42.1% |
| Net Margin % | -55.6% | -86.8% | - | -56.3% | -34.1% | -58.7% | -58.7% |
| ROE % | 48.0% | -29.4% | - | -47.4% | -43.0% | -645.9% | 131.7% |
| ROCE % | -47.6% | -26.2% | - | -45.4% | -21.1% | -13.5% | -79.7% |
Shareholding Pattern
Insiders
21.50%
Institutions
52.78%
Public Float
67.23%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Brandes Investment Partners L.P. | 8.47% | 1.03M | $5.95M |
| 2 | Blackrock Inc. | 5.19% | 628.75K | $3.65M |
| 3 | Vanguard Capital Management LLC | 3.22% | 390.09K | $2.26M |
| 4 | Geode Capital Management, LLC | 1.90% | 229.74K | $1.33M |
| 5 | Dimensional Fund Advisors LP | 1.86% | 224.93K | $1.30M |
| 6 | Groupe La Francaise | 1.76% | 213.54K | $1.24M |
| 7 | CSS LLC | 1.35% | 163.45K | $948.01K |
| 8 | Credit Industriel Et Commercial | 1.19% | 144.36K | $837.28K |
| 9 | Kerrisdale Advisers, Llc | 1.15% | 139.39K | $808.46K |
| 10 | State Street Corporation | 1.12% | 135.74K | $787.29K |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LNSR
No recent headlines available.